FDA approves Sanofi's diabetes drug Toujeo

U.S. health regulators on Wednesday approved Sanofi's diabetes drug Toujeo, a more potent follow-up to the French drugmaker's top-selling insulin product Lantus. The Food and Drug Administration approved the once daily, long-acting basal insulin to treat adults with both type 1 and the far more prevalent type 2 diabetes. The medicine is considered among the most important in Sanofi's pipeline. Sanofi bought some time with a patent infringement lawsuit filed last year against Eli Lilly and Co that would keep a cheaper Lantus generic off the market for 30 months.



via Health News Headlines - Yahoo News http://ift.tt/1At4KBk